The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032

The Business Research Company’s influenza diagnostic market report forecasts the influenza diagnostic market size to grow to $3.37 Billion by 2027, with a CAGR (compound annual growth rate) of more than 6%.

Learn More On The Influenza Diagnostic Market Report 2023 – https://www.thebusinessresearchcompany.com/report/influenza-diagnostic-global-market-report

Influenza Diagnostic Market Size Forecast
The global influenza diagnostic market is expected to grow from $2.42 billion in 2022 to $2.59 billion in 2023 at a compound annual growth rate (CAGR) of 6.9%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global influenza diagnostic market size is expected to grow to $3.37 billion in 2027 at a CAGR of 6.8%.

North America held the largest influenza diagnostic market share.

Key Influenza Diagnostic Market Driver ­– Increase In Funding For Research On Influenza Diagnostics
For instance,in April 2021, the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health, funded $24 million to help five Centres of Excellence for Influenza Research and Response (CEIRR), including the one at St. Jude Children’s Research Hospital. More than $8.9 million of the first year’s funding for St. Jude’s research provided by the federal contract was to understand better, forecast, track, and treat developing influenza and other viruses.

Request for A Sample Of The Global Influenza Diagnostic Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3237&type=smp

Key Influenza Diagnostic Market Trend – Implementing Influenza Diagnostic Tests
Rapid influenza diagnostic tests (RIDTs) are increasingly being implemented in influenza diagnostics. RIDTs are immunoassays which can identify the presence of influenza A and B viral nucleoprotein antigens in respiratory specimens and display the result in a qualitative way (positive vs. negative). It can yield results in a clinically relevant time frame of less than approximately 15 minutes and diagnose patients, who are present with influenza-like illness, mainly if it is performed within the first four days of the onset of symptoms. The rising popularity of RIDT is due to the benefits such as simple to use and rapid diagnosis.

Influenza Diagnostic Market Segment
1) By Traditional diagnostic tests: Rapid influenza diagnostic tests (RIDT), Viral Culture, DFA, Serological assays, Other Traditional diagnostic tests
2) By Molecular diagnostic tests: Reverse Transcription Polymerase Chain Reaction (RT-PCR), Isothermal Nucleic Acid Amplification Tests (INAAT), Loop Mediated Isothermal Based Amplification Assays, Transcription Mediated Isothermal Based Amplification Assays, Transcription Mediated Isothermal Based Amplification Assays, Other Isothermal Nucleic Acid Amplification Tests, Other Molecular Diagnostic Tests
3) By End User: Hospitals & Clinical Laboratories, Diagnostic Reference Laboratories, Academic/Research Institutes, Other End Users

Influenza Diagnostic Market Major Players and Strategies
Major players in the influenza diagnostic market are F. Hoffmann-La Roche Ltd., Quidel Corporation, ?h?rm? F??h?r, Abbott Laboratories, Hologic, Becton Dickinson and Company, DiaSorin S.p.A., Luminex Corporation, Meridian Bioscience Inc. and GenMark Diagnostics.

In February 2021, Thermo Fisher Scientific Inc., a US-based company specialising in clinical development, acquired Mesa Biotech, Inc. for an undisclosed amount. Through this acquisition, Thermo Fisher will increase manufacturing volume, achieve cost efficiencies, and deliver much-needed diagnostics to market faster and at a larger scale. Mesa Biotech, Inc. is a US-based infectious disease diagnostic company.

The Influenza Diagnostic Global Market Report 2023 covers regional data on influenza diagnostic market size, influenza diagnostic market trends and drivers, opportunities, strategies, and influenza diagnostic market competitor analysis. The countries covered in the influenza diagnostic market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA, and the major seven regions are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

Influenza diagnostic is the test used to diagnose influenza including viral culture, serology, rapid antigen testing, reverse transcription-polymerase chain reaction (RT-PCR), immunofluorescence assays, and rapid molecular assays. Influenza, commonly known as flu, is a contagious illness caused by the influenza virus. Three varieties of this virus affect people: type A, type B, and type C. Common symptoms include fever, sore throat, cough, body ache, fatigue, and headache. The market consists of revenues generated by establishments conducting diagnostics tests for influenza virus detection.

View More Reports Related To The Influenza Diagnostic Market –
Molecular Diagnostics Devices And Equipment Global Market Report 2023
Diagnostic Enzyme Global Market Report 2023
Diagnostic Imaging Equipment Global Market Report 2023

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on: